Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Hottinger, A F; Ben Aissa, Assma; Espeli, Vittoria; Squiban, D; Dunkel, Nathalie; Vargas Gomez, Maria Isabel; Hundsberger, T; Mach, Nicolas; Schaller, Karl Lothard; Weber, D C; Bodmer, A; Dietrich, Pierre-Yves

doi:10.1038/bjc.2014.209

Scientific article

Open access

English

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

ContributorsHottinger, A F; Ben Aissa, Assma; Espeli, Vittoria; Squiban, D; Dunkel, Nathalie; Vargas Gomez, Maria Isabel; Hundsberger, T; Mach, Nicolas; Schaller, Karl Lothard; Weber, D C; Bodmer, A; Dietrich, Pierre-Yves

Published inBritish journal of cancer, vol. 110, no. 11, p. 2655-2661

Publication date2014

Abstract

Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma.

Keywords

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity
Brain Neoplasms/mortality/therapy
Chemoradiotherapy
Dacarbazine/administration & dosage/analogs & derivatives
Disease-Free Survival
Female
Glioblastoma/mortality/therapy
Humans
Male
Maximum Tolerated Dose
Middle Aged
Niacinamide/administration & dosage/analogs & derivatives
Phenylurea Compounds/administration & dosage
Treatment Outcome

Affiliation

Research group

Citation (ISO format)

HOTTINGER, A F et al. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. In: British journal of cancer, 2014, vol. 110, n° 11, p. 2655–2661. doi: 10.1038/bjc.2014.209

Article (Published version)

CC BY-NC-SA

Erratum

CC BY-NC-SA

Identifiers

PID : unige:90881
DOI : 10.1038/bjc.2014.209
PMID : 24786603

ISSN of the journal0007-0920

458views

99downloads

Creation01/05/2017 7:00:00 PM

First validation01/05/2017 7:00:00 PM

Update time03/15/2023 1:16:13 AM

Status update03/15/2023 1:16:13 AM

Last indexation10/19/2023 2:58:35 AM

Archive ouverte UNIGE

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Technical informations